

## Geft is dispensable for the development of the second heart field

Xiongwei Fan<sup>1,2,#</sup>, Ning Hou<sup>2,#</sup>, Kaiji Fan<sup>2</sup>, Jiajia Yuan<sup>1</sup>, Xiaoyang Mo<sup>1</sup>, Yun Deng<sup>1</sup>, Yongqi Wan<sup>1</sup>, Yan Teng<sup>2,\*</sup>, Xiao Yang<sup>2,\*</sup> & Xiushan Wu<sup>1,\*</sup>

<sup>1</sup>The Center for Heart Development, Key Lab of MOE for Development Biology and Protein Chemistry, College of Life Sciences, Hunan Normal University, Changsha, <sup>2</sup>State Key Laboratory of Proteomics, Genetic Laboratory of Development and Disease, Institute of Biotechnology, Beijing, P.R. China

**Geft is a guanine nucleotide exchange factor, which can specifically activate Rho family of small GTPase by catalyzing the exchange of bound GDP for GTP. Geft is highly expressed in the excitable tissue as heart and skeletal muscle and plays important roles in many cellular processes, such as cell proliferation, migration, and cell fate decision. However, the *in vivo* role of Geft remains unknown. Here, we generated a Geft conditional knockout mouse by flanking exons 5-17 of Geft with loxP sites. Cre-mediated deletion of the Geft gene in heart using Mef2c-Cre transgenic mice resulted in a dramatic decrease of Geft expression. Geft knockout mice develop normally and exhibit no discernable phenotype, suggesting Geft is dispensable for the development of the second heart field in mouse. The Geft conditional knockout mouse will be a valuable genetic tool for uncovering the *in vivo* roles of Geft during development and in adult homeostasis. (BMB reports 2012; 45(3): 153-158)**

### INTRODUCTION

The Rho family of small GTPases, including RhoA, Rac1, and Cdc42, controls a wide range of cellular processes (1-4). The activation of Rho-GTPases requires the exchange of GDP for GTP, a process catalyzed by the Dbl family of guanine nucleotide exchange factors (GEFs) (5). It was well documented that the Rho family of small GTPases plays important roles in cardiac development. In mice, inhibition of RhoA, Rac1 and

Cdc42 results in embryonic lethality, cardiac morphogenesis disruption, incompleting looping, loss of chamber demarcation and a reduction in cell proliferation (6). In addition, cardiac-specific overexpression of Rac1 in mice results in either a lethal neonatal dilated cardiomyopathy or a resolving transient cardiac hypertrophy (7). Recently, some evidence shows that GEFs play an essential role in cardiogenesis (8, 9). For example, knockdown of Obscurin A, a Rho-GEF, shows cardiac abnormalities ranging from mild cardiac dilatation to severe cardiac hypoplasia in zebrafish (8). Mice null of AKAP13, an AKAP-GEF, display deficient sarcomere formation and thin-walled hearts, and died at E10.5-11.0 (9).

Geft (a new guanine nucleotide exchange factor) is identified as a Rho-family-specific GEF, which is highly expressed in the excitable tissue such as brain, heart and skeletal muscle from the early embryonic stage (10). It was reported that Geft comprises primarily the Dbl homology domain (DH domain) and the pleckstrin homology domain (PH domain). The catalytic guanine nucleotide exchange activity resides in DH domain, whereas PH domain plays important regulatory roles by serving as protein-protein interaction module (11). Previous evidence has showed that Geft regulates cell proliferation and migration (10, 12), neurite outgrowth (13), and mesenchymal cell fate decision (12), through interacting with and catalysing GDP/GTP exchange at RhoA, Rac1 and Cdc42. However, the *in vivo* function of Geft remains elusive.

In this study, we investigated whether Geft participated in heart development. We generated a Geft conditional knockout mouse, and deleted Geft gene in early embryonic heart using Mef2c-Cre transgenic mice. Cardiac-specific Geft knockout mice developed normally and exhibited no discernable phenotype. Our work, for the first time, provided insight into the *in vivo* role of Geft in heart development. Moreover, the Geft conditional knockout mice will be a valuable genetic tool for uncovering the *in vivo* roles of Geft during development and in adult homeostasis.

\*Corresponding authors. Xiushan Wu, Tel: +86-0731-88872780; Fax: +86-0731-88615078; E-mail: xiushanwu@yahoo.com; Xiao Yang, Tel/Fax: +86-10-63895937(0); yangx@nic.bmi.ac.cn; Yan Teng, E-mail: tengyan0919@tom.com

<sup>#</sup>Xiongwei Fan and Ning Hou contributed equally to this work.  
<http://dx.doi.org/10.5483/BMBRep.2012.45.3.153>

Received 23 September 2011, Revised 20 October 2011,  
Accepted 29 October 2011


**Keywords:** Conditional null allele, Cre-loxP, FLPe-Frt, Geft, Heart development

## RESULTS AND DISCUSSION

### Generation of the *Geft* conditional null allele

The murine *Geft* gene consists of 17 exons spanning ~7.4 kb on chromosome 10. *Geft* comprises primarily the Dbl homology (DH) and pleckstrin homology (PH) domains with short N- and C-terminal sequences (14,15). To completely knockout the *Geft* activity through Cre-mediated excision, we decided to tar-

get the genomic region from exon 5 to exon 17, which encodes the entire DH and PH domains. To make the *Geft* conditional targeting construct (Fig. 1A), we used an efficient recombineering-based system mediated by the  $\lambda$  phage Red proteins (16). Following subcloning of a 12.1 kb DNA fragment containing the whole *Geft* sequences, a PGKneo selection cassette, flanked by *Frt* sites and one loxP site at its 3' region, was introduced into intron 4, and a second loxP was placed into a



**Fig. 1.** Generation of the *Geft* conditional null allele. (A) Schematic representation of the wild type *Geft* allele, the *Geft*<sup>fln</sup> targeting vector, the targeted *Geft*<sup>fln</sup> (*Geft*<sup>fln/+</sup>) allele, the *Geft*<sup>fl</sup> (*Geft*<sup>fl/+</sup>) allele, and *Geft*<sup>del</sup> (*Geft*<sup>del/+</sup>) allele. The targeting region consisted of a 3.8 kb 5' arm of homology, a 4.5 kb core region containing exons 5-17, and a 3.8 kb 3' arm of homology. The *Frt*-PGKneo-*Frt*-LoxP cassette was inserted into intron 4 and the second LoxP site was inserted 530 bp downstream of exon 17 of the *Geft* gene. A TK cassette was inserted downstream of 3' arm of homology. FLP-mediated excision of *Frt*-PGKneo-*Frt*-LoxP cassette from the *Geft*<sup>fln</sup> allele resulted in the *Geft*<sup>fl/+</sup> allele, and then Cre-mediated excision of LoxP sites led to *Geft*<sup>del</sup> allele. The open boxes numbered 1-17 represented the exon 1 to exon 17. Open triangles represented the loxP sequence, and black boxes indicated *Frt* sites. The bars represented the 5' external probe for Southern blot analysis and the arrows indicated the position for primers P1, P2, P3, and P4. (B) Southern blot analysis of targeted ES cell clones. Genomic DNA digested by *Kpn* I was hybridized with 5' probe indicated in (A), yielding 5.7 kb wild type and 6.6 kb targeted bands. (C) PCR genotyping of mice carrying *Geft*<sup>+/+</sup> and *Geft*<sup>fl/+</sup> alleles using the primer pair P3 and P4. (D) PCR genotyping of mice carrying *Geft*<sup>+/+</sup>, *Geft*<sup>fl/+</sup> and *Geft*<sup>fl/fl</sup> alleles using the primer pair P1 and P2. (E) Southern blot analysis of mice carrying *Geft*<sup>+/+</sup>, *Geft*<sup>fl/+</sup> and *Geft*<sup>fl/fl</sup> alleles.

site 530 bp downstream of exon 17. The design of the *Geft<sup>fln</sup>* (fn denotes floxP-neo) allele permitted removal of the PGKneo cassette to generate the floxed *Geft* allele (*Geft<sup>fl</sup>*) by using a Flpe deleter mouse line (17), or removal of exons 5-17 of *Geft* gene to generate the *Geft<sup>del</sup>* allele by mating to a Cre deleter line (Fig. 1A).

Targeted ES cells with correct homologous recombination were identified by Southern blot analysis using a 5' flanking probe (Fig. 1B), and were injected into C57BL/6J blastocysts. Chimeras were bred with C57BL/6J female mice, and germline transmission was confirmed by PCR analysis (Fig. 1C). *Geft<sup>fl/+</sup>* heterozygous mice were bred with a deleter line expressing the Flpe recombinase to excise the Frt-flanked pGKneo cassette and generate the *Geft* floxed heterozygous mice (*Geft<sup>fl/+</sup>*). Deletion of this cassette was confirmed by PCR detection of the loxP-Frt sites that remained after Flpe-mediated recombination (Fig. 1D) and Southern blot analysis using the above 5' probe (Fig. 1E). Both *Geft<sup>fl/+</sup>* and *Geft<sup>fl/fl</sup>* mice were viable, fertile, and presented no genotype dependent differences in gross morphological abnormalities, indicating that the floxed *Geft* allele was a functional *Geft* allele.

### Generation of the heart-specific *Geft*-null mice

To assess the *in vivo* excision of the *Geft* conditional knockout allele, the *Geft<sup>fl/fl</sup>* mice were bred with *Mef2c-Cre* transgenic mice, where Cre recombinase is expressed in the second heart field during heart development after E7.5 (18). Cells from the second heart field eventually contribute to form right ventricle and interventricular myocardium (19).

*Mef2c-Cre*-mediated deletion of the loxP-flanked exons 5-17 of *Geft* was confirmed by PCR analysis using a primer set that spanned exons 5-17, which showed a novel 400 bp product specifically in the *Geft<sup>fl/fl</sup>; Mef2c-Cre* heart tissue (Fig. 2A, lane 3), but not in the *Geft<sup>fl/+</sup>; Mef2c-Cre* tail tissue where Cre recombinase does not express (Fig. 2A, lane 2). Furthermore, Southern blot analysis verified the correct excision in the heart tissue of *Geft<sup>fl/+</sup>; Mef2c-Cre* mice (Fig. 2B). Real-time PCR analysis revealed that homozygous *Geft* mutant heart expressed 36 ± 8% of control *Geft* transcripts (Fig. 2C). Consistently, Western blot analysis also revealed that *Geft* expression was dramatically decreased in the homozygous *Geft* mutant heart compared with control heart (Fig. 2D). A small amount of *Geft* RNA and protein were detected in the homozygous *Geft* mutant heart, possibly due to the presence of cells did not come from second heart field. These data demonstrated that this *Geft* allele was recombined to delete exons 5-17 in heart tissue.

### *Geft* is dispensable for mouse second heart field development


Previous study indicates that *Geft* is highly expressed in adult heart tissue (10). RT-PCR analysis revealed that *Geft* was detected in the second heart field at E11.5 and E12.5 when cardiac chamber forms (Fig. 3A).

*Geft<sup>fl/fl</sup>* mice were mated with *Geft<sup>fl/+</sup>; Mef2c-Cre* mice to ob-


tain *Geft* knockout mice (*Geft<sup>fl/fl</sup>; Mef2c-Cre*). This mating resulted in 4 genotypes (*Geft<sup>fl/fl</sup>*, *Geft<sup>fl/+</sup>*, *Geft<sup>fl/fl</sup> Cre* and *Geft<sup>fl/+</sup> Cre*) of offsprings. *Geft<sup>fl/fl</sup>; Mef2c-Cre* mice were born with an expected Mendelian ratio (~25%, Fig. 3B), and survived until adulthood without visible abnormalities.

In morphology the size of the heart in *Geft* knock out mice were normal compared to control (Fig. 3C), and hematoxylin and eosin staining showed a normal structure of right ventricle and interventricular myocardium in *Geft* knock out heart compared with controls (Fig. 3C). We detected no significant changes in heart to body weight and tibia length ratios compared with control mice at the age of one month (Fig. 3D), suggesting no cardiac hypertrophy in *Geft* mutant heart.

These results demonstrated that *Geft* is dispensable for the development of the second heart field giving rise to the right ventricle and outflow tract. A reasonable explanation was that a gene redundancy mechanism existed in mouse heart development compensating for the loss of *Geft* function. In fact, an accumulating body of evidence indicated that other GEFs such as AKAP13 (10), Scambio (20), p114RhoGEF (21), Clg (22) and Trio (23) are abundant in heart. Previous studies have demonstrated that in adult, the Rho family of small GTPases play critical role in cardiac hypertrophy (24). We speculated that under the conditions of various heart stresses, *Geft* deletion might



**Fig. 2.** Generation of the heart-specific *Geft<sup>del</sup>* mice. (A) PCR analysis of the tail or heart tissues from *Geft<sup>fl/fl</sup>*, *Geft<sup>fl/+</sup>*; *Mef2c-Cre* and *Geft<sup>fl/fl</sup>; Mef2c-Cre*; and mice carrying *Geft<sup>fl/fl</sup>* and *Mef2c-Cre(-)* developed normal. (B) Southern blot analysis of the heart tissues from *Geft<sup>fl/fl</sup>* and *Geft<sup>fl/+</sup>; Mef2c-Cre* mice. (C) Real-time PCR result showed a significant decrease of *Geft* transcripts in *Geft<sup>fl/fl</sup> Mef2c-Cre* heart. \*P < 0.05. (D) Western blot analysis revealed that *Geft* expression was dramatically decreased in the homozygous *Geft* mutant heart compared with control heart.



**Fig. 3.** Geft is dispensable for the development of second heart field (A) RT-PCR (left) and Real-time PCR (right) showed Geft highly expressing in the second heart field at E11.5 and E12.5. (B) Mating of Geft<sup>fl/fl</sup>, Geft<sup>fl/+</sup>; Mef2c-Cre resulted in offspring of four genotypes at normal Mendelian ratios. (C) Top: photographs of Geft<sup>fl/fl</sup>, Geft<sup>fl/+</sup>; Mef2c-Cre were taken at the age of one month (originally magnification: 10×). Bottom: Hematoxylin and eosin staining shown a normal structure in one month age heart tissue of Geft<sup>fl/fl</sup>, Geft<sup>fl/+</sup>; Mef2c-Cre (originally magnification: 10×). (D) Heart weight to body weight and tibia length ratios were obtained from adult male Geft<sup>fl/fl</sup>, Geft<sup>fl/+</sup>; Mef2c-Cre at age of one month. SD, n = 5, P > 0.2, HW (heart weight), BW (body weight), TL (tibia length)

lead to abnormal response to these stresses, which need to be further investigated. Moreover, Geft is also highly expressed in the brain, skeletal muscle and lens. Former study found that gene transfer of Geft into cardiotoxin-injured mouse tibialis anterior muscle exerts a powerful promotion of skeletal muscle regeneration *in vivo* and inhibits insulin-induced adipogenesis *in vitro* (10, 12). Previous study also examined the role that Geft plays in the regulation of dendritic spine morphogenesis and neurite outgrowth (13). Through the thoughtful use of tis-

sue specific Cre-expressing mouse strains, deletion of Geft in brain and skeletal muscle tissue will offer further insight into the roles of Geft in above issues.

In summary, we found that Geft was dispensable for the development of the second heart field in mouse. The Geft conditional knockout mouse will be valuable for the investigation of Geft function in development and tissue homeostasis.

## MATERIALS AND METHODS

### Construction of the Geft<sup>fl</sup> allele

The Geft<sup>fl</sup> conditional gene-targeting vector was constructed using recombineering-based system mediated by the  $\lambda$  phage Red protein as previously described (16). A 12.1 kb fragment containing the whole Geft sequences was subcloned from the BAC clone bMQ-117G10 into the plasmid pL253, a modified vector containing a thymidine kinase (TK) negative selection cassette. The 3' loxP site was inserted into 530 bp downstream of exon 17 by bacterial recombineering. A Frt-PGKneo-Frt-loxP cassette with a KpnI site for Southern blot screening was inserted into intron 4 by bacterial recombineering.

### Electroporation of ES cells and generation of Geft<sup>fl</sup> mice

The Geft<sup>fl</sup> targeting vector was linearized with NotI, and electroporated into ES cells (25). ES cells were subjected to selection with G418- and gancyclovir-resistant clones were screened for homologous recombination by Southern blot using KpnI digestion and the 5' external probe with a 5.7 kb WT band and a 6.6 kb targeted band. A 500 bp genomic fragment used as the 5' external probe was amplified by using the primer set Geft5ps/5pa (Geft5ps: 5' ACCTGACTAGGGTCAAGA3'; Geft5pa: 5' CAAAGACAGACACGGGAGA 3'). The primer set P3/P4 (p3: 5'TCCTTTGGTTCAGACTCC3'; p4: 5'CTTGCTGTCTGTGCC3') for screening the correct insertion of 3' loxP site yielded a 290 bp WT band and 350 bp floxed band. Nine colonies showed the correct homologous recombination, and two colonies were microinjected into C57BL/6j blastocysts. Five chimeras were bred with C57BL/6 female mice to obtain germ line transmission. The Geft<sup>fl</sup> mice were genotyped by PCR using the primer pairs P3/P4 and Southern blot using the above 5' probe.

### Generation of Geft<sup>fl</sup> and Geft<sup>del</sup> mice

Geft<sup>fl</sup> heterozygous mice were mated to Flpe transgenic to delete the Frt-flanked pGKneo cassette to produce the Geft<sup>fl</sup> allele. Geft<sup>fl</sup> mice were genotyped with the primer pairs P1/P2 (P1: TTCTGGTCTCTGTGGGA; P2: GGACTTGTGTAGGTC) spanning the remained loxP-Frt sites with 214 bp WT band and 314 bp floxed band. Southern blot analysis using the above 5' probe showed a 4.8 kb band in Geft<sup>fl</sup> allele. Geft<sup>del</sup> mice were generated by crossing the Geft<sup>fl</sup> mice with Mef2c-Cre transgenic mice (18) to delete exons 5-17 of Geft in the heart. Geft<sup>del</sup> mice were genotyped using the primer pairs P1/P4 spanning the entire deleted region, yielding a 400 bp

band. Southern blot analysis using the above 5' probe showed a 8.6 kb band in *Geft<sup>del</sup>* heart. All PCR reactions were carried out under the following conditions: 94°C for 5 min, 30 cycles at 94°C for 15 s, 60°C for 30 s, 72°C for 60 s, and an extension step at 72°C for 5 min.

#### mRNA isolation and real time PCR

Total RNA was extracted from heart tissue using Trizol reagent (Invitrogen). Real-time PCR was performed by a SYBR Green assay with Roche Light Cycler 2.0 system as previously described (26). Expression values were normalized to GAPDH expression. The primer sequences were as follows: *RtGe<sup>fl</sup>*: 5'-CAACGCATTACAGTCACC-3' and 5'-ACAGCACTCTGGACACCT-3'; GAPDH: 5'-TGCCCAGAACATCATCCCT-3' and 5'-GGTCCTCAGTGTAGCCCAAG-3'; *Mef2c*: 5'-CCCCTTCGAGATACCCACAA-3' and 5'-GAAGGTCTGGTGAGTCCAATGG-3'.

#### Western blot

The protein from heart was collected at days 30 after birth. The tissue lysates were separated by 12% SDS-polyacrylamide gels and transferred onto polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). Antibodies for Western blot analysis: *Geft* (sc-161639 ; Santa Cruz) at a 1 : 200 dilution and GAPDH (Sigma) at a 1 : 4,000 dilution as previously described (27).

#### Histology

The hearts were fixed in 4% PFA overnight, then dehydrated through an increasing ethanol series and transferred to paraffin. Paraffin blocks were 6 μm-thick sectioned and transferred onto superfrost slides. Hematoxylin and eosin staining were performed as previously described (28).

#### Acknowledgements

We thank Xiang Gao for kindly providing the phage-based homologous recombination system and FLPe transgenic mice, and Zhong-Zhou Yang for *Mef2c*-Cre transgenic mice. This study was supported in part by the National Natural Science Foundation of China (Nos. 30930054, 30930054, 30970425, 30971105, 30900851, 31171402).

#### REFERENCES

1. Linseman, D. A. and Loucks, F. A. (2008) Diverse roles of Rho family GTPases in neuronal development, survival, and death. *Front Biosci.* **13**, 657-676.
2. Primeau, M. and Lamarche-Vane, N. (2008) A brief overview of the small Rho GTPases. *Med. Sci.* **24**, 157-162.
3. Spindler, V., Schlegel, N. and Waschke, J. (2010) Role of GTPases in control of microvascular permeability. *Cardiovasc. Res.* **87**, 243-253.
4. Samuel, F. and Hynds, D. L. (2010) RHO GTPase signaling for axon extension: is prenylation important? *Mol. Neurobiol.* **42**, 133-142.
5. Lazer, G. and Katzav, S. (2011) Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? *Cell Signal.* **23**, 969-979.
6. Wei, L., Imanaka-Yoshida, K., Wang, L., Zhan, S., Schneider, M. D., DeMayo, F. J. and Schwartz, R. J. (2002) Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts. *Development* **129**, 1705-1714.
7. Sussman, M. A., Welch, S., Walker, A., Klevitsky, R., Hewett, T. E., Price, R. L., Schaefer, E. and Yager, K. (2000) Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active *rac1*. *J. Clin. Invest.* **105**, 875-886.
8. Raeker, M. O., Bieniek, A. N., Ryan, A. S., Tsai, H. J., Zahn, K. M. and Russell, M. W. (2010) Targeted deletion of the zebrafish *obscurin A* RhoGEF domain affects heart, skeletal muscle and brain development. *Dev. Biol.* **337**, 432-443.
9. Mayers, C. M., Wadell, J., McLean, K., Venere, M., Malik, M., Shibata, T., Driggers, P. H., Kino, T., Guo, X. C., Koide, H., Gorivodsky, M., Grinberg, A., Mukhopadhyay, M., Abu-Asab, M., Westphal, H. and Segars, J. H. (2010) The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. *J. Biol. Chem.* **285**, 12344-12354.
10. Guo, X., Stafford, L. J., Bryan, B., Xia, C., Ma, W., Wu, X., Liu, D., Songyang, Z. and Liu, M. (2003) A *Rac/Cdc42*-specific exchange factor, *Geft*, induces cell proliferation, transformation, and migration. *J. Biol. Chem.* **278**, 13207-13215.
11. Schmidt, A. and Hall, A. (2002) Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. *Genes Dev.* **16**, 1587-1609.
12. Bryan, B. A., Mitchell, D. C., Zhao, L., Ma, W., Stafford, L. J., Teng, B. B. and Liu, M. (2005) Modulation of muscle regeneration, myogenesis, and adipogenesis by the Rho family guanine nucleotide exchange factor *GEFT*. *Mol. Cell. Biol.* **25**, 11089-11101.
13. Bryan, B., Kumar, V., Stafford, L. J., Cai, Y., Wu, G. and Liu, M. (2004) *GEFT*, a Rho family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation. *J. Biol. Chem.* **279**, 45824-45832.
14. Lutz, S., Shankaranarayanan, A., Coco, C., Ridilla, M., Nance, M. R., Vettel, C., Baltus, D., Evelyn, C. R., Neubig, R. R., Wieland, T. and Tesmer, J. J. (2007) Structure of *Gaq-p63RhoGEF-RhoA* complex reveals a pathway for the activation of RhoA by GPCRs. *Science* **318**, 1923-1927.
15. Rojas, R. J., Yohe, M. E., Gershburg, S., Kawano, T., Kozasa, T. and Sondek, J. (2007) *Gaq* directly activates *p63RhoGEF* and *Trio* via a conserved extension of the *Dbl* homology-associated pleckstrin homology domain. *J. Biol. Chem.* **282**, 29201-29210.
16. Liu, P., Jenkins, N. A. and Copeland, N. G. (2003) A highly efficient recombineering-based method for generating. *Genome Res.* **13**, 476-484.
17. Farley, F. W., Soriano, P., Steffen, L. S. and Dymecki, S. M. (2000) Widespread recombinase expression using FLPeR (Flipper) mice. *Genesis* **28**, 106-110.
18. Verzi, M. P., McCulley, D. J., De Val, S., Dodou, E. and Black, B. L. (2005) The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. *Dev. Biol.* **287**, 134-145.

19. Prall, O. W., Menon, M. K., Solloway, M. J., Watanabe, Y., Zaffran, S., Bajolle, F., Biben, C., McBride, J. J., Robertson, B. R., Chaulet, H., Stennard, F. A., Wise, N., Schaft, D., Wolstein, O., Furtado, M. B., Shiratori, H., Chien, K. R., Hamada, H., Black, B. L., Saga, Y., Robertson, E. J., Buckingham, M. E. and Harvey, R. P. (2007) An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. *Cell* **128**, 947-959.
20. Curtis, C., Hemmerlyckx, B., Haataja, L., Senadheera, D., Groffen, J. and Heisterkamp, N. (2004) Scambio, a novel guanine nucleotide exchange factor for Rho. *Mol. Cancer* **23**, 10.
21. Blomquist, A., Schworer, G., Schablowski, H., Psoma, A., Lehnen, M., Jakobs, K. H., and Rumenapp, U. (2000) Identification and characterization of a novel Rho-specific guanine nucleotide exchange factor. *Biochem. J.* **352**, 319-325.
22. Himmel, K. L., Bi, F., Shen, H., Jenkins, N. A., Copeland N. G., Zheng, Y., and Largaespada, D. A. (2002) Activation of clg, a novel dbl family guanine nucleotide exchange factor gene, by proviral insertion at evi24, a common integration site in B cell and myeloid leukemias. *J. Biol. Chem.* **277**, 13463-13472.
23. Debant, A., Serra-Pages, C., Seipel, K., O'Brien, S., Tang, M., Park, S. H. and Streuli, M. (1996) The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 5466-5471.
24. Lezoualc'h, F., Métrich, M., Hmitou, I., Duquesnes, N. and Morel, E. (2008) Small GTP-binding proteins and their regulators in cardiac hypertrophy. *J. Mol. Cell. Cardiol.* **44**, 623-632.
25. Yang, X., Li, C., Herrera, P. L. and Deng, C. X. (2002) Generation of Smad4/Dpc4 conditional knockout mice. *Genesis* **32**, 81-82.
26. Li, F., Lan, Y., Wang, Y., Wang, J., Yang, G., Meng, F., Han, H., Meng, A., Wang, Y. and Yang, X. (2011) Endothelial smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch. *Dev. Cell.* **20**, 291-302.
27. Guo, S. L., Peng, Z., Yang, X., Fan, K. J., Ye, H., Li, Z. H., Wang, Y., Xu, X. L., Li, J., Wang, Y. L., Teng, Y. and Yang, X. (2011) miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. *Int. J. Biol. Sci.* **7**, 567-574.
28. Wang, J., Xu, N., Feng, X., Hou, N., Zhang, J., Cheng, X., Chen, Y., Zhang, Y. and Yang, X. (2005) Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. *Circ. Res.* **97**, 821-828.